Group 1: Eli Lilly & Co. - Eli Lilly is reducing the cash cost of its weight-loss drug Zepbound on its direct-to-consumer platform, with prices now ranging from $299 to $449 per month, down from $349 to $499 [2] - This price cut follows agreements made by President Donald Trump with Eli Lilly and competitor Novo Nordisk to enhance accessibility and affordability of their weight-loss drugs [2] Group 2: Disney - The Thanksgiving box office performance is expected to be one of the best in history, with an estimated $294 million in revenue over the holiday weekend [4] - Disney's "Zootopia 2" led the box office, generating approximately $156 million [4] Group 3: Airbus - European-listed shares of Airbus fell due to reports of an industrial quality issue affecting the fuselage panels of its A320-family aircraft, leading to delayed deliveries [7] - Airbus recently faced a software glitch that grounded about 6,000 of its A320-family planes over the holiday weekend [8] Group 4: Family Businesses in Memorial Products - Family businesses providing personalized memorial products are facing challenges from increasing cremation rates and tariff hikes imposed by Trump [9] - Despite tariffs, these businesses continue to import granite due to higher labor costs in the U.S. and the necessity of certain types of stone only available internationally [10]

Core Viewpoint - The AIDS Healthcare Foundation (AHF) is launching a mobile billboard to criticize Gilead Sciences for its pricing strategy regarding the HIV prevention drug lenacapavir, demanding that it be made affordable and accessible [1] Group 1: Company Actions - AHF's mobile billboard will circle the venue of the Global Pharma & Biotech Summit in London on November 11-12 [1] - The billboard carries a message directed at Gilead and its CEO Daniel O'Day, urging them to "Make Lenacap" [1] Group 2: Industry Context - The event coincides with the Global Pharma & Biotech Summit, highlighting ongoing discussions in the pharmaceutical industry regarding drug pricing and accessibility [1]

Group 1: Technology Sector Developments - Google has successfully cleared a significant regulatory hurdle with the U.S. Department of Justice regarding its proposed $32 billion acquisition of Wiz Inc., which aims to enhance its cloud security offerings [2] - Hon Hai Precision Industry reported an 11.3% increase in October sales, indicating strong demand in the technology manufacturing sector, particularly for AI infrastructure components [5] Group 2: Pharmaceutical Sector Insights - Novo Nordisk's CEO has not commented on rumors of a potential deal with the White House to reduce prices for GLP-1 drugs, which could drop to $150 per month from over $1,000, reflecting ongoing political and public pressure on drug affordability [4] Group 3: Economic Indicators in Europe - France's industrial production rose by 0.8% month-over-month and 1.3% year-over-year in October, significantly exceeding forecasts and indicating a healthier start to the fourth quarter for the French industry [3] - Sweden's services sector experienced a decline in October, with the PMI Services index falling to 55.4 from 57.9, suggesting a moderation in growth despite remaining above the expansion threshold [6]